来源：人民日报健康客户端 春节聚会，推杯换盏、把酒言欢——热闹是真的，但身体在"悄悄加班"也是真的。你以为酒精只是伤 胃？错。医生警告：酒精的伤害，远比你想的更可怕。肝脏、心脏、大脑、血管……一杯酒下去，全身 都在替你扛。 今天这篇文章，并非劝你一定要戒酒，而是劝你再别用错方式饮酒，这6种喝法太伤身。 这6种喝酒方式，危害翻倍 各种酒混在一起喝，首先就会让我们不自觉地饮酒过量。而且，两种以上的酒混着喝还会表现出某 种"协同作用"，对人体伤害更大。长沙市中心医院重症医学科主任医师杨勇2024年在医院微信公众号刊 文介绍，不同种类的酒精饮品混合饮用会加速酒精的吸收，增加肝脏和胃肠的负担，从而显著提高急性 酒精中毒的风险。② 1. 服药期间喝酒 正在服用药物的人可千万不能因为"兴致"，而忽视了酒与药同服的危害。中南大学湘雅二医院药学部主 管药师席洋2023年在医院微信公众号刊文提醒，若服用与酒精有相互作用的药物，应停药后至少间隔7 天再饮酒。老年人、肝肾功能不全等特殊人群间隔时间应延长。此外，喝酒后建议在3天内避免服用与 酒精有相互作用的药物。① 除了头孢不能与酒同时服用，还有其他一些药物服药期间也不能饮酒： 镇静 ...

Group 1 - The article addresses common misconceptions about various topics, including AI content generation, NFC technology, flu vs. cold, allergy medications, electric toothbrushes, dietary oils, carbon plate running shoes, sun protection, dried food storage, and electric vehicles in rain [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Group 2 - The article emphasizes the importance of scientific understanding and debunking myths to enhance public knowledge and safety [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16].

Core Viewpoint - The article discusses the distinction between rhinovirus colds and influenza, highlighting symptoms, recovery times, and treatment recommendations for rhinovirus infections [1][2][3] Group 1: Symptoms and Differences - Rhinovirus colds primarily present with nasal congestion, runny nose, and sneezing, with minimal or low-grade fever, and typically resolve in 5-7 days [2] - Influenza symptoms include high fever (above 39°C), body aches, and fatigue, with recovery taking 7-10 days and potential lingering fatigue [2] - The article emphasizes that if symptoms are limited to nasal issues without severe discomfort, it is likely a rhinovirus cold, whereas sudden high fever and body pain indicate influenza [2] Group 2: Treatment and Management - There are no specific antiviral medications for rhinovirus; oseltamivir is ineffective against it [3] - Antibiotics should not be used unless there is a bacterial co-infection, as they can disrupt gut flora [3] - Non-pharmacological methods such as rest, hydration, light diet, and maintaining indoor ventilation are recommended for symptom relief [3] Group 3: Caution in Symptom Management - Patients should avoid forceful nose blowing, especially if experiencing severe nasal congestion or if they have underlying health conditions like hypertension or cardiovascular diseases, as it may lead to complications [3] - Proper techniques for blowing the nose are advised to prevent potential health risks [3] - While rhinovirus colds are generally self-limiting and have a good prognosis, severe symptoms warrant prompt medical attention [3]

Core Viewpoint - The article discusses the safety of antihistamines and nasal steroids used for allergy treatment, clarifying that they do not cause addiction and emphasizing the importance of consistent medication use to prevent worsening allergy symptoms [1][3]. Group 1: Antihistamines and Nasal Steroids - The main types of antihistamines available in the market are second-generation antihistamines, such as cetirizine and loratadine, which do not affect the central nervous system [3]. - Nasal steroids, commonly used for allergies, act locally and do not enter systemic circulation, further ensuring their safety [3]. Group 2: Side Effects and Precautions - Some antihistamines may cause drowsiness and impaired concentration, which poses risks for individuals engaged in high-concentration tasks such as operating machinery or driving [5].

Group 1 - The National Healthcare Security Administration (NHSA) has released the 11th batch of centralized drug procurement documents, involving 55 types of drugs across various categories such as anti-infection, anti-tumor, anti-allergy, diabetes, and cardiovascular medications [2][3] - The new bidding rules aim to avoid vicious competition among pharmaceutical companies while ensuring quality and affordability for patients, aligning with the cost control requirements of medical insurance [3][4] - The new rules include a "revival" mechanism for mainstream brands that did not win in the first round, allowing them to qualify at the highest proposed winning price, recognizing the market value of quality brands [3][4] Group 2 - The reporting rules have shifted from counting by drug generic names to allowing medical institutions to report by specific brand names, emphasizing respect for doctors' prescribing autonomy and ensuring patient access to medications [4] - The impact of the new procurement rules on drug companies and the industry will require observation over time, with expectations that centralized procurement will accelerate industry reshuffling, particularly affecting companies with severe product homogeneity [4] - Continuous feedback from stakeholders and timely evaluations of the new rules' impacts are essential for maintaining the effectiveness and vitality of the centralized procurement policy, ensuring patients receive reasonably priced and safe medications [4]

Core Viewpoint - The new procurement rules aim to prevent pharmaceutical companies from engaging in harmful price competition while ensuring quality and affordability for patients, aligning with medical insurance cost control requirements [2][3]. Group 1: New Procurement Rules - The latest round of centralized drug procurement involves 55 types of drugs, including those for infections, tumors, allergies, diabetes, and cardiovascular diseases [2]. - The new bidding rules optimize the price difference calculation anchor, moving away from a simple lowest price model, requiring the lowest bidder to justify their pricing and commit to not pricing below cost [2][3]. - A "revival" mechanism has been introduced, allowing mainstream brands that did not win in the first round to qualify at the highest proposed winning price, recognizing the market value of quality brands [3]. Group 2: Quality and Compliance - The new rules impose strict quality controls, requiring that the production lines of bidding drugs have no violations of quality management standards in the past two years, with comprehensive inspections and product sampling by regulatory authorities [3]. - The reporting rules have shifted from generic drug names to allowing medical institutions to report based on specific brand names, emphasizing respect for doctors' prescribing autonomy and ensuring patient access to medications [3]. Group 3: Industry Impact and Future Outlook - The new procurement rules are expected to accelerate the reshaping of the pharmaceutical industry, with many companies likely to be eliminated due to severe product homogeneity [4]. - Companies are reminded that competing solely on price is not sustainable; they must focus on quality and innovation to thrive in the industry [4]. - Continuous feedback from stakeholders is essential for evaluating the impact of the new rules, ensuring that the procurement policy remains effective and beneficial for both patients and companies [4].

Group 1: Industry Overview - Approximately 70% of allergy medications in China are produced in Hainan, with a significant contribution from Wante Pharmaceutical (Hainan) Co., Ltd, a private enterprise with over 20 years in the region [1] - Hainan Baolu Aquatic Technology Co., Ltd has developed the 21st generation of tilapia fry, achieving a growth rate improvement of 300% compared to the first generation, exporting 1 billion fry annually to global markets [1] - As of June 2023, Hainan has 3.6044 million private business entities, accounting for 97.54% of the province's total, contributing 60% of GDP, 80% of tax revenue, and nearly 90% of employment [1] Group 2: Innovation and R&D - Jindan Technology Co., Ltd has transformed from a single transformer product company to a smart manufacturing leader with nearly 7 billion yuan in annual revenue, investing 356 million yuan in R&D in 2024 [2] - Hainan Huayan Collagen Technology Co., Ltd focuses on high-value utilization of marine resources, converting fish by-products into small molecule peptides for various applications, supported by a highly educated R&D team [2] - In 2024, the top 20 private enterprises in Hainan are expected to invest a total of 3.763 billion yuan in R&D, holding 1,199 valid patents and participating in the formulation of 335 standards [2] Group 3: Policy Support - Jingrun Pearl, the first company in Hainan's pearl processing industry to benefit from a 30% processing value-added tax exemption, has imported 16,300 pearls this year, saving over 1 million yuan in taxes [3] - The 10.56 billion yuan lithium hydroxide project in Yangpu is expected to generate over 2 billion yuan in annual output value, benefiting from Hainan's zero-tariff policy [3] - Hainan has implemented a series of policies, including a 15% income tax reduction for businesses and individuals, to enhance the business environment and support private enterprises [4] Group 4: Business Environment - Hainan's first batch of soybean oil from AOSK International Grain and Oil was exported to India, showcasing the province's efficient business environment that allows rapid project completion [5] - The Hainan government has introduced measures to optimize the business environment, including a one-stop service platform for policies and direct communication channels between government and enterprises [5] - The Hainan Free Trade Port is set to enhance the global competitiveness of private enterprises, with companies like Hainan Shengsen Pharmaceutical Co., Ltd planning to establish R&D centers and expand international markets [6]